Ewelina Mamcarz, St. Jude Children's Research Hospital (IMAGE)
Caption
Ewelina Mamcarz, M.D., presents research at the 2017 ASH conference that indicates that the St. Jude XSCID gene therapy has been well tolerated and effective for infants as young as 2 months old.
Credit
Peter Barta / St. Jude Children's Research Hospital.
Usage Restrictions
None
License
Licensed content